loader2
Partner With Us NRI

Piramal Pharma Ltd

Company details

97.30
101.45
97.30
182.20
6M Return 0.00%
1Y Return -44.79%
Mkt Cap.(Cr) 12,004.79
Volume 274,176
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 274,176

Open Free Demat Account Online with ICICIDIRECT

Piramal Pharma Ltd.

Q2FY23 Quarterly Result Announced for Piramal Pharma Ltd.

Piramal Pharma announced Q2FY23 results:

  •  Revenue from operation grew by 11% to Rs 3,202 crore versus Rs 2,889 crore in H1FY22
    • CDMO business grew by 12% YoY
    • Complex Hospital Generic business grew by 11% YoY
    • India's Consumer Healthcare business grew by 12% YoY
  • Normalised EBITDA in H1FY23 was Rs 376 crore with EBITDA margin of 12%
  • Capital Expenditure for H1FY23 was Rs 427 crore
  • Successfully cleared 22 regulatory inspections and 111 customer audits in H1FY23
  •  Released Piramal Pharma Sustainability Report FY22

Nandini Piramal, Chairperson, Piramal Pharma Ltd, said, “We announce our first results post demerger as an independent and focused pharma company. Over the last 10 years, we have made several strategic choices that have helped nurture and scale our business and establish Piramal Pharma (PPL) as a leading global pharmaceuticals player.

For the quarter and half year that ended on September 2022, our business has delivered a resilient performance despite multiple internal and external challenges. We expect to deliver a much improved performance in second half of the current financial year. Historically we have had a greater skew of sales and profits in the second half of the year and this year is no different.

We have a vision to grow all our businesses to significant scale over the medium term and have strong growth levers in place for each of them. We continue to make investments to drive growth in these businesses.”

 

Result PDF

View Other Company Results

FINANCIALS

Sales

Operating Profit

Profit after Tax

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after Tax

PE

Debt/Equity

P BV

COMPARISION

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 6,696.60 Cr FV: 10.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 17,871.26 -28,732.63
LAST 3M 35,065.84 -30,146.79
LAST 6M 57,360.50 38,576.46
LAST 12M 186,944.70 -113,961.48

Piramal Pharma Limited - Updates

Feb 03, 2023 l NSE Announcement

Piramal Pharma to hold board meeting

Feb 02, 2023 l BSE Announcement

Piramal Pharma Limited - Board Meeting

Feb 02, 2023 l NSE Announcement

Date Action Type Ratio
No data found

INFORMATION

Stock PE (TTM)

31.24

Promoter Holding

34.79%

Book Value

56.1795

ROCE

9.13%

ROE

7.48%

Description

  • Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market. The CDMO business offers integrated services ranging from drug discovery and clinical development to commercial manufacturing of active pharmaceutical ingredients and formulations. The Company caters to a large customer base by leveraging an extensive network of facilities across US, Canada, UK, and India providing global delivery capabilities. Its diversified manufacturing footprint enables customer/market proximity and cost-efficient production. The customers benefit from reduced time-to-market and operational complexity and lower supply chain costs to meet their requirements. The Company is among the leading players in India in the self-care space, with established brands like Saridon, Supradyn, Lacto Calamine, Little`s, Tetmosol, i-Pill and Polycrol. Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. It has a global footprint with manufacturing capabilities across 15 facilities spanning across India, US, the UK and Canada. It also has global distribution network in over 100 countries. The Company`s global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions. In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL). In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA). In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs. On 7th October 2021, the Board of Directors had approved a Composite Scheme of Arrangement, which was entered into between the Company, Piramal Pharma Limited (PPL), Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to PPL, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of PPL) into PPL; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL. Further, in April 2022, the Company, jointly with PPL, CCPL, HPPL and PFPL had filed a Company Application to Scheme with the NCLT. Pursuant to an Order dated May 12, 2022, the Demerged Scheme was approved on July 5, 2022. The NCLT sanctioned the Scheme on August 12, 2022, where the Scheme of demerger was effective from August 18, 2022. In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines.

No Data Found

AGM Date (Month) :
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 543635
NSE Code : PPLPHARMA
Book Closure Date (Month) :
BSE Group : T
ISIN : INE0DK501011

ICICIdirect Piramal Pharma Ltd FAQ

You can buy Piramal Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Piramal Pharma Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Feb 03, 2023 04:01 PM the closing price of Piramal Pharma Ltd was ₹ 100.60.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Feb 03, 2023 04:01 PM, the market cap of Piramal Pharma Ltd stood at ₹ 12,004.79.
The latest PE ratio of Piramal Pharma Ltd as of Feb 03, 2023 04:01 PM is 31.24
The latest PB ratio of Piramal Pharma Ltd as of Feb 03, 2023 04:01 PM is 0.56
The 52-week high of Piramal Pharma Ltd is ₹ 182.20 while the 52-week low is ₹ 97.30

Download Our App

market app
market app